Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Nov 7;2019(11):CD006401.
doi: 10.1002/14651858.CD006401.pub5.

Statins for children with familial hypercholesterolemia

Alpo Vuorio  1 , Jaana Kuoppala  2 , Petri T Kovanen  3 , Steve E Humphries  4 , Serena Tonstad  5 , Albert Wiegman  6 , Euridiki Drogari  7 , Uma Ramaswami  8
Affiliations
Meta-Analysis

Statins for children with familial hypercholesterolemia

Alpo Vuorio et al. Cochrane Database Syst Rev. .

Abstract

Background: Familial hypercholesterolemia is one of the most common inherited metabolic diseases and is an autosomal dominant disorder meaning heterozygotes, or carriers, are affected. Those who are homozygous have severe disease. The average worldwide prevalence of heterozygous familial hypercholesterolemia is at least 1 in 500, although recent genetic epidemiological data from Denmark and next generation sequencing data suggest the frequency may be closer to 1 in 250. Diagnosis of familial hypercholesterolemia in children is based on elevated total cholesterol and low-density lipoprotein cholesterol levels or DNA-based analysis, or both. Coronary atherosclerosis has been detected in men with heterozygous familial hypercholesterolemia as young as 17 years old and in women with heterozygous familial hypercholesterolemia at 25 years old. Since the clinical complications of atherosclerosis occur prematurely, especially in men, lifelong treatment, started in childhood, is needed to reduce the risk of cardiovascular disease. In children with the disease, diet was the cornerstone of treatment but the addition of lipid-lowering medications has resulted in a significant improvement in treatment. Anion exchange resins, such as cholestyramine and colestipol, were found to be effective, but they are poorly tolerated. Since the 1990s studies carried out on children aged 6 to 17 years with heterozygous familial hypercholesterolemia have demonstrated significant reductions in their serum total and low-density lipoprotein cholesterol levels. While statins seem to be safe and well-tolerated in children, their long-term safety in this age group is not firmly established. This is an update of a previously published version of this Cochane Review.

Objectives: To assess the effectiveness and safety of statins in children with heterozygous familial hypercholesterolemia.

Search methods: Relevant studies were identified from the Group's Inborn Errors and Metabolism Trials Register and Medline. Date of most recent search: 04 November 2019.

Selection criteria: Randomized and controlled clinical studies including participants up to 18 years old, comparing a statin to placebo or to diet alone.

Data collection and analysis: Two authors independently assessed studies for inclusion and extracted data.

Main results: We found 26 potentially eligible studies, of which we included nine randomized placebo-controlled studies (1177 participants). In general, the intervention and follow-up time was short (median 24 weeks; range from six weeks to two years). Statins reduced the mean low-density lipoprotein cholesterol concentration at all time points (high-quality evidence). There may be little or no difference in liver function (serum aspartate and alanine aminotransferase, as well as creatinine kinase concentrations) between treated and placebo groups at any time point (low-quality evidence). There may be little or no difference in myopathy (as measured in change in creatinine levels) (low-quality evidence) or clinical adverse events (moderate-quality evidence) with statins compared to placebo. One study on simvastatin showed that this may slightly improve flow-mediated dilatation of the brachial artery (low-quality evidence), and on pravastatin for two years may have induced a regression in carotid intima media thickness (low-quality evidence). No studies reported rhabdomyolysis (degeneration of skeletal muscle tissue) or death due to rhabdomyolysis, quality of life or compliance to study medication.

Authors' conclusions: Statin treatment is an effective lipid-lowering therapy in children with familial hypercholesterolemia. Few or no safety issues were identified. Statin treatment seems to be safe in the short term, but long-term safety remains unknown. Children treated with statins should be carefully monitored and followed up by their pediatricians and their care transferred to an adult lipidologist once they reach 18 years of age. Large long-term randomized controlled trials are needed to establish the long-term safety issues of statins.

PubMed Disclaimer

Conflict of interest statement

Alpo Vuorio: none known. Jaana Kuoppala: none known. Petri Kovanen: I have been paid for consultancy by Raisio and Unilever, and for lectures by Raisio, Unilever, Amgen, and Aegerion. Steve Humphries: The Children' UK Pediatric Register has been funded 2014‐2016 by the BHF and 2016‐2018 by a grant from the International Atherosclerosis Society. Serena Tonstad: none known. Albert Wiegman: none known. Euridiki Drogari: none known. Uma Ramaswami: none known.

Figures

1
1
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Avis 2010 {published data only}
    1. Avis HJ, Hutten BA, Gagné C, Langslet G, McCrindle BW, Wiegman A, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. Pediatric Cardiology 2010;55(11):1121‐6. - PubMed
Braaskamp 2015a {published data only}
    1. Braaskamp MJ, Stefanutti C, Langslet G, Drogari E, Wiegmann A, Hounslow N, et al. Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk. Journal of Pediatrics 2015;167(2):338‐43. - PubMed
Clauss 2005 {published data only}
    1. Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, et al. Pediatrics Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005;116(3):682‐8. - PubMed
Couture 1998 {published data only}
    1. Couture P, Brun LD, Szots F, Lelièvre M, Gaudet D, Després J‐P, et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadian with heterozygous familial hypercholesterolemia. Arteriosclerosis Thrombosis and Vascular Biology 1998;18(6):1007‐12. - PubMed
de Jongh 2002a {published data only}
    1. Jongh S, Stalenhoef AF, Tuohy MB, Mercuri M, Bakker HD, Kastelein JJ. Efficacy, safety and tolerability of simvastatin in children with familial hypercholesterolaemia: rationale, design, and baseline characteristics. Clinical Biochemistry and Metabolism 2003;11(32):157‐62.
    1. Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. Journal of the American College of Cardiology 2002;40(12):2117‐21. [] - PubMed
    1. Jongh S, Ose L, Szamosi T, Gagné C, Lambert M, Scott R, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized, double‐blind, placebo‐controlled trial with simvastatin. Circulation 2002;106(17):2231‐7. - PubMed
    1. Jongh S, Stalenhoef AF, Tuohy MB, Mercuri M, Bakker HD, Kastelein JJ. Efficacy, safety and tolerability of simvastatin in children with familial hypercholesterolaemia. Clinical Drug Investigation 2002;22(8):533‐40.
Knipscheer 1996 {published data only}
    1. Knipscheer HC, Boelen CC, Kastelein JJ, Diermen DE, Groenemeijer BE, Ende A, et al. Short‐term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatric Research 1996;39(5):867‐71. - PubMed
McCrindle 2003 {published data only}
    1. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with a familial hypercholesterolemia or severe hyperlipidemia: A multicenter, randomized, placebo‐controlled trial. Journal of Pediatrics 2003;143(1):74‐80. - PubMed
Stein 1999 {published data only}
    1. Stein EA, Illingworth DR, Kwiterovich Jr. PO, Liacouras CA, Siimes MA, Jacobson MS, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia. JAMA 1999;281(2):137‐44. - PubMed
Wiegman 2004 {published data only}
    1. Wiegman A, Hutten BA, Groot E, Rodenburg J, Bakker HD, Büller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. JAMA 2004;292(3):331‐7. - PubMed

References to studies excluded from this review

Athyros 2002 {published data only}
    1. Athyros VG, Papageorgiou AA, KOntopoulos AG. Long‐term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia. Atherosclerosis 2002;163(1):205‐6. - PubMed
Braaskamp 2015b {published data only}
    1. Braamskamp MJ, Kusters DM, Wiegmann A, Avis HJ, Wijburg FA, Kastelein JJ, et al. Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood. Atherosclerosis 2015;241(2):427‐32. - PubMed
Braaskamp 2015c {published data only}
    1. Braaskamp MJ, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagné C, et al. Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study. Journal of Clinical Lipidology 2015;9(6):741‐50. - PubMed
Carreau 2011 {published data only}
    1. Carreau V, Girardet JP, Bruckert E. Long‐term follow‐up of statin treatment in a cohort of children with familial hypercholesterolemia: Efficacy and tolerability. Pediatric Drugs 2011;13(4):267‐75. - PubMed
Chan 2016 {published data only}
    1. Chan DC, Pang J, Barrett PH, Sullivan DR, Mori TA, Burnett JR, et al. Effect of omega‐3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy. Nutrition, Metabolism and Cardiovascular Diseases 2016;26(12):1140‐5. [CENTRAL: 1247168; CRS: 5500050000000549; EMBASE: 613255561] - PubMed
Dirisamer 2003 {published data only}
    1. Dirisamer A, Hachemian N, Bucek RA, Wolf F, Reiter M, Widhalm K. The effect of low‐dose simvastatin in children with familial hypercholesterolemia: a 1‐year observation. European Journal of Pediatrics 2003;162(6):421‐5. - PubMed
Gandelman 2011 {published data only}
    1. Gandelman K, Glue P, Laskey R, Jones J, LaBadie R, Ose L. An eight‐week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatric Cardiology 2011;32(4):433‐41. - PMC - PubMed
Harada‐Shiba 2018 {published data only}
    1. Harada‐Shiba M, Kastelein JJ, Hovingh K, Ray KK, Ohtake A, Arisaka O, et al. Efficacy and safety of pitvastatin in children and adolescents with familial hypercholesterolemia in Japan and Europe. Journal of Atherosclerosis and Thrombosis 2018;25:422‐429. - PMC - PubMed
Hedman 2003 {published data only}
    1. Hedman M, Neuvonen PJ, Neuvonen N, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clinical Pharmacology and Therapy 2003;74(2):178‐85. - PubMed
Hedman 2005 {published data only}
    1. Hedman M, Matikainen T, Fohr A, Lappi M, Piippo S, Nuutinen M, et al. Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: A prospective clinical follow‐up study. Journal of Clinical Endocrinology and Metabolism 2005;90(4):1942‐52. - PubMed
Lambert 1996 {published data only}
    1. Lambert M, Lupien PJ, Gagne C, Levy E, Blaichman S, Langlois S, et al. Treatment of familial hypercholesterolemia in children and adolescents: Effect of lovastatin. Pediatrics 1996;97(5):619‐28. - PubMed
Langslet 2016 {published data only}
    1. Langslet G, Breazna A, Drogari E. A 3‐year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology 2016;10(5):1153‐62. - PubMed
McCrindle 2002 {published data only}
    1. McCrindle BW, Helsden E, Cullen‐Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatric Research 2002;51(6):715‐21. - PubMed
Raal 1997 {published data only}
    1. Raal FJ, Pitcher G, Rubinsztein DC, Lingenhel A, Utermann G. Statin therapy in a kindred with both apolipoprotein B and low‐density lipoprotein receptor gene defects. Atherosclerosis 1997;129(1):97‐102. - PubMed
Sinzinger 2004 {published data only}
    1. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolemia rarely tolerate statin treatment because of muscular problems. British Journal of Clinical Pharmacology 2004;57(4):525‐8. - PMC - PubMed
Stefanutti 1999 {published data only}
    1. Stefanutti C, Lucani G, Vivenzio A, Giacomo S. Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drugs Under Experimental and Clinical Research 1999;25(1):23‐8. - PubMed
Stein 1989 {published data only}
    1. Stein EA. Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis 1989;9(Suppl 1):l145‐51. - PubMed
Stein 2016 {published data only}
    1. Stein EA, Dann EJ, Wiegmann A, Skovby F, Gaudet D, Sokal E, et al. A randomized, double‐blind, placebo‐controlled, multi‐center, Cross‐over study of rosuvastatin in children and adolescents (aged 6 to <18 years) with homozygous familial hypercholesterolemia (HOFH). JACC 2016;67(13):1855.
Tada 2016 {published data only}
    1. Tada H, Kobayashi J, Kawashiri MA, Miashita K, Nohara A, Inazu A, et al. Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three‐drug lipid‐lowering combination therapy. Lipids in Health and Disease 2016;15:66. - PMC - PubMed
Teramoto 2016 {published data only}
    1. Teramoto T, Kobayashi M, Tasaki H, Yagyu H, Higashikata T, Takagi Y, et al. Efficacy and safety of alirocumab in Japanese patients With heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins ‐ ODYSSEY JAPAN Randomized Controlled Trial. Ciruculation Journal 2016;80(9):1980‐7. - PubMed
van der Graaf 2006 {published data only}
    1. Graaf A, Nieman MC, Firth JC, Wolmarans KH, Marais AD, De GE. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolemia. Acta Paediatrica 2006;95(11):1461‐6. - PubMed

Additional references

Arambepola 2007
    1. Arambepola C, Farmer AJ, Perera R, Neil HA. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: A systematic review and meta‐analysis. Atherosclerosis 2007;195(2):339‐47. - PubMed
Avis 2007
    1. Avis HJ, Vissres EA, Stein FA, Wijburg MD, Trip JJP, Kastelein JJ, et al. A systematic review and meta‐analysis of statin therapy in children with familial hypercholesterolemia. Arteriosclerosis Thrombosis and Vascular Biology 2007;27(8):1803‐10. - PubMed
Backes 2003
    1. Backes JM, Howard PA. Association of HMG‐CoA reductase inhibitors with neuropathy. Annals of Pharmacotherapy 2003;37(2):274‐8. - PubMed
Bays 2006
    1. Bays H. Statin safety: An overview an assessment of the data ‐ 2005. American Journal of Cardiology 2006;97(8A):6C‐26C. - PubMed
Benn 2016
    1. Benn M, Watts GF, Tybjærg‐Hansen A, Nordetsgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. European Heart Journal 2016;37(17):1384‐94. - PubMed
Besseling 2015
    1. Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 2015;313(10):358‐61. - PubMed
Bradford 1991
    1. Bradford RH, Shear CL, Chremos AN, Dujovne C, Dowton M, Franklin FA, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Archives of Internal Medicine 1991;151(1):43‐9. - PubMed
Brass 2006
    1. Brass LM, Alberts MJ, Sparks L. National Lipid Association Statin Safety Task Force Neurology Expert Panel: An assessment of statin safety by neurologist. American Journal of Cardiology 2006;97(8A):86C‐88C. - PubMed
Cenedella 1996
    1. Cenedella RJ. Cholesterol and cataracts. Survey of Opthalmology 1996;40(4):320‐37. - PubMed
Chalasani 2004
    1. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126(5):1287‐92. - PubMed
Chodick 2010
    1. Chodick G, Heymann AD, Flash S, Kokia E, Shalev V. Persistence with statins and incident cataract: a population‐based historical cohort study. Annals of Epidemiology 2010;20(2):136‐42. - PubMed
Chong 2004
    1. Chong PH, Boskovich A, Sevkovic N, Bartt RE. Statin‐associated peripheral neuropathy: Review of the literature. Pharmacotherapy 2004;24(9):1194‐203. - PubMed
Cohen 2006
    1. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. American Journal of Cardiology 2007;8(Suppl 1):S77‐S81. - PubMed
Daniels 2008
    1. Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in children. Pediatrics 2008;122(1):198‐208. - PubMed
de Denus 2004
    1. Denus S, Spinler SA, Miller K, Peterson AM. Statins and live toxicity: a meta‐analysis. Pharmacotherapy 2004;24(5):584‐91. - PubMed
de Jongh 2002b
    1. Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. Journal of the American College of Cardiology 2002;40(12):2117‐21. - PubMed
Descamps 2011
    1. Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2012;218(2):272‐80. - PubMed
Fong 2012
    1. Fong DS, Poon KY. Recent statin use and cataract surgery. American Journal of Opthalmology 2012;153(2):222‐8. - PubMed
Futema 2013
    1. Futema M, Whittall RA, Kiley A, Steel LK, Cooper JA, Badmus E, et al. Analysis of the frequency and spectrum on mutation recognised to cause familial hypercholesterolaemia in routine clinical practise in a UK specialist hospital clinic. Atherosclerosis 2013;229(1):161‐8. - PMC - PubMed
Futema 2015
    1. Futema M, Shah S, Cooper JA, Li K, Whittall RA, Sharifi M, et al. Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. Clinical Chemistry 2015;61(1):231‐8. - PMC - PubMed
Goldberg 2011
    1. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology 2011;5(3 Suppl):S1‐S8. - PubMed
Goldstein 1979
    1. Goldstein JL, Helgeson JA, Brown MS. Inhibition of cholesterol synthesis with compactin renders growth of cultured cells dependent on the low density lipoprotein receptor. Journal of Biological Chemistry 1979;254(12):5403‐9. - PubMed
Goldstein 1990
    1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343(6257):425‐30. - PubMed
Goldstein 1995
    1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D editor(s). The Metabolic Bases of Inherited Diseases. 7th Edition. New York, NY: McGraw‐Hill Book Co, 1995:1981‐2030.
Golomb 2013
    1. Golomb BA. The importance of monitoring adverse events in statin, and other, clinical trials. Clinica Investigation 2013;3(10):913‐6.
Graham 2005
    1. Graham CA, McIlhatton BP, Kirk CW, Beattie ED, Lyttle K, Hart P, et al. Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. Atherosclerosis 2005;182(2):331‐40. - PubMed
Harris 1995
    1. Harris ML, Bron AJ, Brown NAkeech AC, Wallendszus KR, Armitage JM, MacMahon S, et al. Absence of effect of simvastatin on the progression of lens opacitis in a randomised placebo controlled study. Oxford Cholesterol Study Group. Bristish Journal of Opthalmology 1995;79(11):996‐1002. - PMC - PubMed
Heath 1999
    1. Heath KE, Gudnason V, Humphries SE, Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol‐lowering response of the HMG‐CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1999;143(1):41‐54. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011a
    1. Higgins JP, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011b
    1. Higgins JP, Altman DG, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hippisley‐Cox 2010
    1. Hippisley‐Cox, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197. - PMC - PubMed
Hoffmann 2002
    1. Hoffmann U, Dirisamer A, Heher S, Kostner K, Widhalm K, Neunteufl T. Relation of flow‐mediated vasodilatation and coronary arterial calcium in young patients with heterozygous familial hypercholesterolemia. American Journal of Cardiology 2002;90(1):70‐3. - PubMed
Humphries 2006a
    1. Humphries SE, Cranston T, Allen M, Middleton‐Price H, Fernandez MC, Senior V, et al. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. Journal of Molecular Medicine (Berl) 2006;84(3):203‐14. - PubMed
Humphries 2006b
    1. Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar A, et al. Genetic causes of Familial Hypercholesterolaemia in UK patients: Relation to plasma lipid levels and coronary heart disease risk. Journal of Medical Genetics 2006;43(12):943‐9. - PMC - PubMed
Iacocca 2018
    1. Iacocca MA, Chora JR, Carrié A, Freiberger T, Leigh SE, Defesche JC, et al. ClinVar database of global familial hypercholesterolemia‐associated DNA variants. Human Mutation 2018;39(11):2018. - PMC - PubMed
Joy 2009
    1. Joy TR, Hegele RA. Narrative Review: statin‐related myopathy. Annals of Internal Medicine 2009;150(12):858‐68. - PubMed
Joyce 2017
    1. Joyce NR, Zachariah JP, Eaton CB, Trivedi AN, Wellenius GA. Statin use and the risk of type 2 diabetes mellitus in children adolescents. Acta Pediatrica 2017;17(5):515‐22. - PMC - PubMed
Jüni 2001
    1. Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42‐6. - PMC - PubMed
Khera 2016
    1. Khera A, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. Journal American College of Cardiology 2016;67(22):2578‐89. - PMC - PubMed
Koeijvoets 2005
    1. Koeijvoets KC, Rodenburg J, Hutten BA, Wiegman A, Kastelein JJ, Sijbrands EJ. Low‐density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima‐media thickness trial. Circulation 2005;112(20):3168‐73. - PubMed
Kotze 1993
    1. Kotze MJ, Villiers WJ, Steyn K, Kriek JA, Marais AD, Langenhoven E, et al. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arteriosclerosis and Thrombosis 1993;13(10):1460‐8. - PubMed
Kusters 2014
    1. Kusters DM, Avis HJ, Groot E, Wijburg FA, Kastelein JJ, Wiegmann A, et al. Ten‐year follow‐up after initiation of statin therapy in children with familial hyeprcholesterolemia. JAMA 2014;312(10):1055‐7. - PubMed
Kwiterovich 1974
    1. Kwiterovich PO Jr, Fredrikson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. Journal of Clinical Investigation 1974;53(5):1237‐49. - PMC - PubMed
Law 2006
    1. Law M, Rudnicka AR. Statin safety: A systematic review. American Journal of Cardiology 2006;97(8A):52C‐60C. - PubMed
Leigh 2016
    1. Leigh S, Futema M, Taylor‐Beadling A, Williams M, Dunnen JT, Humphries SE. The UCL low‐density lipoprotein receptor gene variant database: pathogenicity update. Journal of Medical Genetics 2016;54(4):217‐23. - PMC - PubMed
Leonard 1976
    1. Leonard JV, Fosbrooke AS, Lloyd JK, Wolff OH. Screening for familial hyper‐beta‐lipoproteinemia in children in hospital. Archives of Diseases in Children 1976;51(11):842‐7. - PMC - PubMed
Leuschen 2013
    1. Leuschen J, Mortensen EM, Frei CR, Mansi EA, Panday V, Mansi I. Association of statin use with cataracts: a propensity score‐matched analysis. JAMA Opthalmolology 2013;131(11):1427‐34. - PubMed
Mabuchi 1989
    1. Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989;79(2):225‐32. - PubMed
McCrindle 2007
    1. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high‐risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007;115(14):1948‐67. - PubMed
McCrindle 2012
    1. McCrindle BW. Familial hypercholesterolemia in children and adolescents. Current Opinion in Lipidology 2012;23(6):525‐31. - PubMed
McKenney 2006
    1. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Task Force. American Journal of Cardiology 2006;97(8A):89C‐94C. - PubMed
Miltiadous 2005
    1. Miltiadous G, Xenophontos S, Bairaktari E, Ganotakis M, Cariolou M, Elisaf M. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmagogenetic Genomics 2005;15(4):219‐25. - PubMed
Myant 1993
    1. Myant NB. Familial defective apolipoprotein B‐100: A review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis 1993;104(1‐2):1‐18. - PubMed
Navarese 2013
    1. Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta‐anaysis of impact of different types and doses of statins on new‐onset diabetes mellitus. American Journal of Cardiology 2013;111(8):1123‐30. - PubMed
NICE 2008
    1. National Institute of Clinical Excellence. Identification and management of familial hypercholesterolaemia ‐ clinical guideline CG71. http://www.nice.org.uk/nicemedia/pdf/CG071NICEGuideline.pdf (accessed 01 October 2013).
Nordestgaard 2013
    1. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana I, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European Heart Journal 2013;34(45):3478‐90. - PMC - PubMed
O'Connor 1990
    1. O'Connor P, Feely J, Shepherd J. Lipid lowering drugs. BMJ 1990;300(6725):667‐72. - PMC - PubMed
Pang 2016
    1. Pang J, Landsberg PJ, Watts GF. International developments in the care of familial hypercholesterolemia: Where now and where to next?. Journal of Atherosclerosis and Thrombosis 2016;23(5):505‐19. - PubMed
Pasternak 2002
    1. Pasternak RC, Smith SC, Bairey‐Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation 2002;106(8):1024‐8. - PubMed
Pedersen 1996
    1. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine 1996;156(18):2085‐92. - PubMed
Poustie 2001
    1. Poustie VJ, Rutherford P. Dietary treatment for familial hypercholesterolaemia. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD001918] - DOI - PubMed
Sattar 2010
    1. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta‐analysis of randomised statin trials. Lancet 2010;375(9716):735‐42. - PubMed
SIGN 2007
    1. Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease. www.sign.ac.uk/pdf/sign97.pdf (accessed 01 October 2013).
Sjouke 2015
    1. Sjouke B, Kusters DM, Besseling J, Defesche JC, Sijbrands EJ, Roeters van Lennep JE, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype‐phenotype relationship, and clinical outcome. European Heart Journal 2015;36(9):560‐5. - PubMed
Skoumas 2014
    1. Skoumas J, Liontou C, Chrysohoou C, Masoura C, Aznaouridis K, Pitsavos C, et al. Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. Atherosclerosis 2014;237(1):140‐5. - PubMed
Staffa 2002
    1. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. New England Journal of Medicine 2002;346(7):539‐40. - PubMed
Starr 2008
    1. Starr B, Hadfiled SG, Hutten BA, Landsberg P, Leren TP, Damgaard D, et al. Development of sensitive and specific age‐ and gender‐specific low‐density lipoprotein cholesterol cutoffs for diagnosis of first‐degree relatives with familial hypercholesterolaemia in cascade testing. Clinical Chemistry and Laboratory Medicine 2008;46(6):791‐803. - PubMed
Sullivan 2012
    1. Sullivan DR, Hamilton‐Craig I, Bockxmeer F, Watts GF, CSANZ Cardiac Genetics Diseases Council Writing Group. INTERIM guidelines for the diagnosis and management of familial hypercholesterolaemia. Heart Lung and Circulation 2012;21(3):159‐62. - PubMed
Sun 1998
    1. Sun XM, Patel D, Knight BL, Soutar AK. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid‐lowering drug therapy in heterozygous familial hypercholesterolemia. The Familial Hypercholesterolaemia Regression Study Group. Atherosclerosis 1998;136(1):175‐85. - PubMed
Swerdlow 2015
    1. Swerdlow DI, Presii D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, et al. HMG‐coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015;385(9965):351‐61. - PMC - PubMed
Talmud 2013
    1. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, et al. Use of low‐density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case‐control study. Lancet 2013;381(9874):1293‐1301. - PubMed
Tonstad 1996
    1. Tonstad S, Joakimsen O, Stensland‐Bugge E, Leren TP, Ose L, Russell D, et al. Risk factors related to carotid intima‐media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arteriosclerosis, Thrombosis, and Vascular Biology 1996;16(8):984‐91. - PubMed
Umans 2002
    1. Umans‐Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Low‐density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 2002;106(24):3031‐6. - PubMed
van der Graaf 2011
    1. Graaf A, Avis HJ, Kusters DM, Vissers MN, Hutten BA, Defesche JC, et al. Molecular basis of autosomal dominant hypercholesterolemia. Circulation 2011;123(11):1167‐73. - PubMed
Vlahos 2014
    1. Vlahos AP, Naka KK, Bechlioulis A, Theoharis P, Vakalis K, Moutzouri E, et al. Endothelial dysfunction, but not structural atherosclerosis, is evident early in children with heterozygous familial hypercholesterolemia. Pediatric Cardiology 2014;35(1):63‐70. - PubMed
Vohl 2002
    1. Vohl MC, Szots F, Leliévre M, Lupien PJ, Bergeron J, Gagné C, et al. Influence of LDL receptor gene mutation and apo E polymorphis on liporpotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis 2002;160(2):361‐8. - PubMed
Vuorio 2001
    1. Vuorio AF, Aalto‐Setälä K, Koivisto UM, Turtola H, Nissen H, Kovanen PT, et al. Familial hypercholesterolaemia in Finland: Common, rare and mild mutations of the LDL receptor and their clinical consequences. Annals of Medicine 2001;33(6):410‐21. - PubMed
Vuorio 2013
    1. Vuorio A, Docherty KF, Humphries SE, Kuoppala J, Kovanen PT. Statin treatment of children with familial hypercholesterolemia ‐ trying to balance incomplete evidence of long‐term safety and clinical accountability: Are we approaching a consensus?. Atherosclerosis 2013;226(2):315‐20. - PubMed
Vuorio 2016
    1. Vuorio A, Strandberg T, Schneider WJ, Kovanen PT. Statins and new‐onset diabetes mellitus ‐ a risk lacking in familial hypercholesterolaemia. Journal of Internal Medicine 2016;279(4):358‐61. - PubMed
Wald 2016
    1. Wald DS, Bestwick JP, Morris JK, Whyte K, Jenkins L, Wald NJ. Child‐parent familial hypercholesterolemia screening in primary care. New England Journal of Medicine 2016;375(17):1628‐37. - PubMed
Wray 1996
    1. Wray R, Neil H, Rees J. Screening for hyperlipidaemia in childhood. Recommendations of the British Hyperlipidaemia Association. Journal of Royal College of Physicians London 1996;30(2):115‐8. - PMC - PubMed

References to other published versions of this review

Vuorio 2010
    1. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S, et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD006401.pub2] - DOI - PubMed
Vuorio 2014
    1. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD006401.pub3] - DOI - PubMed
Vuorio 2017
    1. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews 2017, Issue 7. [DOI: 10.1002/14651858.CD006401.pub3] - DOI - PMC - PubMed

Publication types

Substances